TC BioPharm gains MHRA nod for trial amendment
| TCBP Stock | USD 1.95 0.22 10.14% |
Slightly above 60% of TC BioPharm's investor base is looking to short. The analysis of the overall investor sentiment regarding TC BioPharm Holdings suggests that many traders are alarmed. TC BioPharm's investing sentiment overview a quick insight into current market opportunities from investing in TC BioPharm Holdings. Many technical investors use TC BioPharm Holdings stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
TCBP |
TC BioPharm gains MHRA nod for trial amendment
Read at investing.com
 |
TC BioPharm Fundamental Analysis
We analyze TC BioPharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TC BioPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TC BioPharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
TC BioPharm is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
TC BioPharm Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TC BioPharm stock to make a market-neutral strategy. Peer analysis of TC BioPharm could also be used in its relative valuation, which is a method of valuing TC BioPharm by comparing valuation metrics with similar companies.
Peers
TC BioPharm Related Equities
| ZURA | Zura Bio | 13.33 | ||||
| IMMX | Immix Biopharma | 12.66 | ||||
| ICU | LMF Acquisition | 7.45 | ||||
| PALI | Palisade Bio | 1.22 | ||||
| SONN | Sonnet Biotherapeutics | 0.65 | ||||
| PHIO | Phio Pharmaceuticals | 0.70 | ||||
| ALLR | Allarity Therapeutics | 1.23 | ||||
| REVB | Revelation Biosciences | 1.67 | ||||
| UNCY | Unicycive Therapeutics | 1.79 | ||||
| VRAX | Virax Biolabs | 2.34 | ||||
| ZVSA | ZyVersa Therapeutics | 3.42 | ||||
| BDRX | Biodexa Pharmaceticals | 3.48 | ||||
| QNRX | Quoin Pharmaceuticals | 13.89 | ||||
| RNAZ | Transcode Therapeutics | 21.43 |
Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.